Identification of microRNAs in the intergenic regions of braf genes
In Papillary Thyroid Carcinoma (PTC), the BRAFV600E mutation represents 90% of cases, considered a point mutation due to the transversion
Day: September 30, 2026
In Papillary Thyroid Carcinoma (PTC), the BRAFV600E mutation represents 90% of cases, considered a point mutation due to the transversion